Aimmune therapeutics, inc. (AIMT)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Sep'15Jun'15Sep'14Jun'14
Product revenue, net

575

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Costs and operating expenses
Cost of revenue

257

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses
Research and development

36,463

30,125

30,558

31,988

31,316

33,029

31,691

35,254

33,446

28,654

21,063

22,191

17,417

16,958

15,888

11,820

9,976

3,850

3,131

2,469

1,801

Selling, general and administrative

49,138

-

-

-

23,712

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total costs and operating expenses

85,858

-

-

-

55,028

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

-

36,861

34,044

31,200

-

25,404

21,285

18,559

16,673

12,986

11,226

10,813

8,924

8,343

6,353

6,466

5,723

5,174

4,246

660

967

Total operating expenses

-

66,986

64,602

63,188

-

58,433

52,976

53,813

50,119

41,640

32,289

33,004

26,341

25,301

22,241

18,286

15,699

9,024

7,377

3,129

2,768

Loss from operations

-85,283

-66,986

-64,602

-63,188

-55,028

-58,433

-52,976

-53,813

-50,119

-41,640

-32,289

-33,004

-26,341

-25,301

-22,241

-18,286

-15,699

-9,024

-7,377

-3,129

-2,768

Interest income

978

925

1,315

1,710

1,901

1,482

1,394

1,400

708

-

-

-

-

-

-

-

-

-

-

-

5

Interest expense

2,229

1,250

1,260

1,262

1,144

28

28

28

29

-

-

-

-

-

-

-

-

-

-

-

-

Interest income, net

221

1,156

-12

-90

34

-37

-63

-78

-43

530

497

507

471

225

155

147

176

33

1

-

-

Loss before provision for income taxes

-86,313

-66,155

-64,559

-62,830

-54,237

-57,016

-51,673

-52,519

-49,483

-41,110

-31,792

-32,497

-25,870

-

-

-

-

-

-

-

-

Provision for income taxes

119

743

-104

48

29

-18

29

33

17

56

-

-

-

-

-

-

-

-

-

-

-

Net loss

-86,400

-66,898

-64,455

-62,878

-54,266

-56,998

-51,702

-52,552

-49,500

-41,166

-31,792

-32,497

-25,870

-25,076

-22,086

-18,139

-15,523

-8,991

-7,376

-3,129

-2,763

Other comprehensive loss, net of tax:
Foreign currency translation adjustment

10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain on available-for-sale investments

73

-60

-97

174

171

-

-

-

-

-34

61

-13

-95

-41

-17

25

94

-2

-

-

-

Comprehensive loss

-86,349

-66,958

-64,552

-62,704

-54,095

-

-

-

-

-41,200

-31,731

-32,510

-25,965

-25,117

-22,103

-18,114

-15,429

-8,993

-7,376

-3,129

-

Net loss per share, basic and diluted

-1.34

-1.06

-1.03

-1.01

-0.87

-0.95

-0.89

-0.91

-0.92

-0.81

-0.63

-0.65

-0.52

-0.56

-0.53

-0.43

-0.37

-0.36

-1.60

-1.07

-0.94

Weighted average shares used in computing net loss per common share, basic and diluted

64,514

63,257

62,619

62,334

62,022

-

-

-

-

50,847

50,458

50,230

50,069

45,513

41,997

41,800

41,694

25,149

4,619

2,926

2,926